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Abstract
Background: Cervical cancer screening with assays detecting DNA of high-risk human papillomavirus (hrHPV) types
is more effective than cytology-based screening. This study completes the diagnostic accuracy assessment
conducted previously within the framework of VALGENT-2 (Validation of HPV genotyping Tests) and aims to
determine whether the reproducibility of Xpert HPV is in line with international validation criteria.
Methods: Validation of new hrHPV DNA assays requires demonstration of good reproducibility and non-inferior
clinical accuracy for cervical precancer compared to a standard comparator assay. The international reproducibility
criteria are: lower bound of 95% confidence interval of the intra- and inter-laboratory agreement regarding
detection of high-risk HPV DNA exceeding 87% with kappa ≥0.5.
Results: The Xpert HPV assay showed high intra-laboratory reproducibility with an overall positivity/negativity
agreement of 96.9% and a kappa of 0.925. Inter-laboratory testing showed an agreement of 97.8% with a
kappa of 0.948.
Conclusions: The Xpert HPV assay fulfills the HPV test reproducibility criterion requirement for use in cervical
cancer screening.
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Background
High level of evidence from large randomized trials cur-
rently exists which indicates that human papillomavirus
(HPV) based assays are more effective than cytology
screening to reduce the burden of severe cervical dysplasia
and cancer [1]. Two HPV assays were used in the random-
ized trials, Hybrid Capture 2 (HC2) and GP5+/6+ poly-
merase chain reaction-enzyme immunoassay (PCR-EIA).
International guidelines have been widely adopted for
the clinical validation of novel HPV tests. In a popula-
tion of screened women of at least 30 years of age, the
novel HPV test should demonstrate non-inferior sensi-
tivity and specificity for cervical intraepithelial neoplasia
grade 2+ (CIN2+) compared to the standard comparator
tests (Hybrid Capture 2 (HC2) HPV DNA test or GP5
+/6+ PCR EIA) [2]. In addition, the novel HPV test
should demonstrate high intra- and inter-laboratory
reproducibility with a lower confidence bound not less
than 87% while maintaining a kappa value higher than
or equal to 0.5.
Based on meta-analysis, a list was established of
high-risk HPV (hrHPV) assays that fulfill the
cross-sectional performance criteria for cervical cancer
screening [3]. This list is continuously updated as soon
as data on new HPV assays become available. This current
study aims to assess the intra- and inter-laboratory repro-
ducibility of the Xpert HPV assay.
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Xpert HPV is a non-batch real-time PCR assay capable
of detecting 14 hrHPV types (HPV16, − 18, − 31, − 33,
− 35, − 39, − 45, − 51, − 52, − 56 -58, − 59, − 66, − 68)
within the run time of 1 h. The assay utilizes six fluor-
escent channels for the detection of individual types of
hrHPV, groups of hrHPV, and the human reference
gene. Fluorescent channel 1 detects HPV 16; fluores-
cent channel 2 detects HPV 18 and − 45; fluorescent
channel 3 detects HPV 31, − 33, − 35, − 52, − 58; fluor-
escent channel 4 detects HPV 51, − 59; fluorescent
channel 5 detects HPV 39, − 56, − 66, − 68 and fluores-
cent channel 6 is used for Sample Adequacy Control
(SAC).
The fulfillment of the international equivalency criteria
of Xpert HPV regarding sensitivity and specificity to
detect cervical precancer has been evaluated as part of a
separate study (VALGENT) [7, 9].
Methods
VALGENT is an established comprehensive study design
allowing validation of high-risk HPV DNA assays which
potentially can be used for primary cervical cancer
screening [2, 9]. It includes comparing the sensitivity
and specificity for CIN2+ with a standard comparator
test. Non inferior accuracy of the Xpert HPV assay com-
pared to the GP5+/6+ PCR-assay was demonstrated in
the second installment of VALGENT using samples
collected from women attending the Scottish cervical
cancer screening program [9]. The current study address
the intra- and inter-reproducibility of the Xpert HPV
assay using residual material of cervical specimens
remnant after HPV testing with the AML qPCR and
microscopic cytological processing. The cervical samples
were collected in PreservCyt liquid based cytology media
(ThinPrep®) (Hologic, San Diego, CA, USA) according to
the manufacturers recommendations in agreement with
European guidelines. Samples were collected between
February 2016 and November 2016. Three aliquots of
1 ml of the original Preservcyt solution were prepared
and stored at room temperature. The time span between
specimen collection and preparation was maximum
3 days. The first two were tested independently with the
Xpert HPV assay of the department of Cytopathology
and Molecular Diagnostics at Algemeen Medisch
Laboratorium (AML) with an interval of 4 weeks. A
third aliquot was sent to laboratory of the Department
of Microbiology and Immunology, Ghent University
Hospital, Ghent, Belgium where it was tested again with
the Xpert HPV assay.
The study set contained residual cervical cell material
collected from 510 women attending cervical cancer
screening in Belgium [10]. The composition was deter-
mined as recommended in the international guideline
for validation of new hrHPV DNA tests [2], prescribing
30% of high-risk HPV positive specimen tested with a
clinically validated assay. The study set contained
aliquots form 357 hrHPV-negative and 153 hrHPV-posi-
tive women. HPV positivity was determined by the RIA-
TOL real-time PCR targeting E6/7 genes of 18 HPV
genotypes [4].
The RIATOL real-time qPCR allows genotyping of 18
HPV types for 14 hrHPV types (HPV 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66, and 68), one probable
hrHPV type (HPV 53), two low-risk types (HPV 6, 11)
and one undetermined risk type (HPV 67). The AML
HPV test has been clinically validated according to the
international guidelines [5]. A detailed description of the
laboratory developed validation test has been published
previously. The RIATOL real-time qPCR generates a
quantitative correlation by generating signal strength in
the form of Ct-values (cycle threshold). The Ct-values
are calculated by determining the point at which the
fluorescence exceeds a threshold limit [6]. Ct-values are
inversely proportional to the amount of target nucleic
acid in a sample. Studies have shown that AML HPV
test is highly sensitive for the detection of HPV geno-
types [7].
The overall percentage of agreement was computed as
the proportion of concordant results (positive + negative
concordant test results) over all test results with corre-
sponding binomial exact 95% confidence intervals.
Cohen’s Kappa values were calculated and 95% CI as
proposed by Fleiss [8]. Intra-reproducibility assessment
was based on the two Xpert HPV testings in the AML
laboratory. Inter-reproducibility assessment was based
on the first testing in AML and the testing at the Uni-
versity of Gent. The reproducibility validation criterion
for new hrHPV DNA assays usable in cervical screening
was considered as fulfilled when the left 95% confidence
interval (CI) bound for hrHPV concordance exceeded
87% and the kappa > 0.5.
The Ct-values per fluorescent channel were recorded
during each run. To identify the consistency of these
values during the intra- and inter-laboratory tests, the
average, minimal and maximal difference in Ct-values of
the samples were calculated per fluorescent channel.
Results
The results from hrHPV testing with Xpert HPV
showed high intra-laboratory reproducibility with an
agreement of 96.9% (95% CI, 95.0–98.2%) (494/510
samples) and a kappa of 0.925 (95% CI 0.888–961).
The inter-laboratory test showed an excellent
agreement of 97.8% (95% CI, 96.2–98.9%), 499/510
samples) with a kappa of 0.948 (95% CI 0.917–0.978).
The results of intra- and inter-laboratory reproducibility
are represented in Table 1.
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Results were evaluated per fluorescent channel. The
overall agreement within the intra-laboratory runs was
close to 100%, with the lower confidence bound not less
than 96%. The lowest overall agreement of 98% was
detected in fluorescent channel 3 (HPV 31, 33, 35, 52,
and 58) between the intra-laboratory run 1 and run 2.
Other runs showed that the agreement within fluores-
cent channel 3 was slightly lower. The kappa value of
the intra-laboratory reproducibility run was close to 1.
There were inconsistencies noticed in the Ct- values
annotated to the sample within the three Xpert HPV
runs. Table 2 represents the summary of the samples
with inconsistent Ct-values in the five fluorescent
channels during the intra-and inter-laboratory tests. The
average difference within the Ct-values of the five fluor-
escent channels was 1.1 and varied between 0.1 and 3.2.
The largest difference in Ct-values (MAX 8.6, 6.7, and 8.4)
can be observed in fluorescent channel 3 (HPV type 31,
33, 35, 52, and 58) for the three runs, respectively.
The overall agreement within the inter-laboratory runs
was close to 100%, with the lower confidence bound not
less than 97% while a slightly lower agreement was
found for fluorescent channel 3. The kappa value of the
inter-laboratory reproducibility run was close to 1. The
reproducibility of the Xpert HPV per fluorescent
channel is represented in Table 3.
Discussion and conclusions
During the intra- and inter- laboratory reproducibility
testing 1530 Xpert HPV assay runs were conducted.
Sixteen samples that were identified as INVALID by the
Xpert HPV assay. These samples were re-tested and the
results of the assay turned out to be valid after
re-testing. This implies that the internal control at the
initial testing was indicating assay failure rather than
sample failure. Xpert HPV has shown excellent reprodu-
cibility but it also has an error rate of approximately 1%.
An error rate of 1% can be significant when large numbers
of samples are analyzed with Xpert HPV.
Xpert HPV showed excellent overall intra-laboratory
reproducibility with an agreement of 96.9% and a kappa
of 0.925). The overall reproducibility was close to 100%
for HPV 16 and HPV 18/45, confirming reliability of
Xpert HPV for the main high-risk types. Besides that the
inter-laboratory test showed an excellent agreement of
97.8% with a kappa of 0.948 and great reproducibility
statistics for HPV16 and HPV18/45. A small number of
discrepancies were found, but almost all of them
appeared to be linked to detection limit, Ct-value or
borderline issues.
Our data confirm that the intra-laboratory reproduci-
bility and inter-laboratory agreement of Xpert HPV
largely exceeds the requirements formulated in the
Table 1 Intra and inter laboratory reproducibility
Intra-laboratory reproducibilitya
Xpert HPV – AML Run 2 Total
Xpert HPV –AML Run 1 Negative Positive
Negative 353 4 357
Positive 12 141 153
Total 365 145 510
Inter-laboratory agreementb
Xpert HPV UZ Ghent Total
Xpert HPV –AML Run 1 Negative Positive
Negative 356 1 357
Positive 10 143 153
Total 366 144 510
Inter-laboratory agreementc
Xpert HPV UZ Ghent Total
Xpert HPV –AML Run 2 Negative Positive
Negative 154 3 357
Positive 4 149 153
Total 157 153 510
aThe overall HPV test agreement 96.9% (95% CI, 95.0–98.2%) KAPPA value of
0.925 (95% CI 0.888–0.961)
bThe overall HPV test agreement 97.8% (95% CI, 96.2–98.9%) KAPPA value of
0.948 (95% CI 0.917–0.978)
cThe overall HPV test agreement 98.6% (95% CI, 97.6–99.6%) KAPPA value of
0.967 (95% CI 0.943–0.991)
Table 2 Difference in Ct-values between intra- and inter-
laboratory runs
N AVG Range
MIN MAX
AML run 1 versus AML run 2
FC 1 30 1.1 0.1 3.2
FC 2 22 0.9 0.1 3.8
FC 3 64 1.4 0.1 8.6
FC 4 29 1.0 0.1 3.7
FC 5 42 1.3 0.2 4.8
AML run 1 versus Ghent run
FC 1 31 1.2 0.1 3.3
FC 2 21 1.3 0.1 3.9
FC 3 63 1.3 0.1 6.7
FC 4 29 1.3 0.1 7.1
FC 5 40 1.3 0.1 4.2
AML run 2 versus Ghent run
FC 1 27 1.2 0.1 3.7
FC 2 23 1.2 0.1 5.0
FC 3 65 1.2 0.1 8.4
FC 4 29 1.2 0.1 6.1
FC 5 43 1.3 0.1 6.0
FC Fluorescent channel, N Number of samples, AVG Average, MAX maximum,
MIN minimum
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international guidelines for the validation of a novel
hrHPV test with respect to its use in primary cervical
cancer screening. Our study completes the VALGENT-2
clinical validation study which demonstrated a relative
sensitivity and relative specificity of hrHPV testing with
Xpert HPV compared to GP5+/6+ PCR of 0.984 (95% CI
0.931–1.040, pnon-inferiority [pni] = 0.019) and 1.006 (95% CI
0.997–1.016, pni < 0.0001), respectively, among screened
women aged 30 or older [9]. Considering the VALGENT
findings with the reproducibility results from the current
study, we can conclude that the Xpert HPV can be added
to the list of assays that fulfill international criteria for
primary cervical cancer screening [3]. In addition, Xpert
HPV is hereby the only point of care test fulfilling these
criteria.
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Table 3 Overall agreement, lower and upper confidence bound, and the KAPPA value of each flourescent channel per run
Agreement 95% CI Kappa Kappa 95% CI
Lower bound Upper bound Lower bound Upper bound
Intra-laboratory run 1versusIntra-laboratory run 2
Fluorescent channel 1 99.4% 98.8% 100% 0.99 97.0% 100%
Fluorescent channel 2 99.6% 99.1% 100% 0.99 97.8% 100%
Fluorescent channel 3 98.0% 96.8% 99.2% 0.95 92.4% 98.2%
Fluorescent channel 4 99.2% 98.5% 100% 0.98 96.3% 100%
Fluorescent channel 5 98.8% 97.9% 99.8% 0.97 95.0% 99.4%
Intra-laboratory run 1 versusInter-laboratory (Ghent)
Fluorescent channel 1 99.6% 99.1% 100% 0.99 97.8% 100%
Fluorescent channel 2 99.6% 99.1% 100% 0.99 97.8% 100%
Fluorescent channel 3 98.8% 97.9% 99.8% 0.97 94.9% 99.4%
Fluorescent channel 4 99.2% 98.5% 100% 0.98 96.3% 100%
Fluorescent channel 5 98.6% 97.6% 99.6% 0.97 94.3% 99.1%
Intra-laboratory run 2 versusInter-laboratory (Ghent)
Fluorescent channel 1 99.4% 98.8% 100% 0.99 97.0% 100%
Fluorescent channel 2 100% 100% 100% 1.00 100% 100%
Fluorescent channel 3 98.8% 97.9% 99.8% 0.97 95.0% 99.4%
Fluorescent channel 4 99.2% 98.5% 100% 0.98 96.3% 100%
Fluorescent channel 5 99.8% 99.4% 100% 1.00 98.6% 10%
CI Confidence interval, Fluorescent channel FC 1 detects HPV16, FC2 detects HPV18 and HPV45, FC3 detects HPV31,33,35,52,58, FC4 detects HPV51,59, FC5 detects
HPV 39,56,66,68
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